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FUS binds the CTD of RNA
polymerase II and regulates
its phosphorylation at Ser2
Jacob C. Schwartz,1,2,3 Christopher C. Ebmeier,2
Elaine R. Podell,1,2,3 Joseph Heimiller,4
Dylan J. Taatjes,2 and Thomas R. Cech1,2,3,5
1Howard Hughes Medical Institute, 2Department of Chemistry
and Biochemistry, 3BioFrontiers Institute, 4Department
of Molecular, Cellular, and Developmental Biology, University
of Colorado at Boulder, Boulder, Colorado 80309, USA
Mutations in the RNA-binding protein FUS (fused in
sarcoma)/TLS have been shown to cause the neurode-
generative disease amyotrophic lateral sclerosis (ALS),
but the normal role of FUS is incompletely understood.
We found that FUS binds the C-terminal domain (CTD)
of RNA polymerase II (RNAP2) and prevents inappropriate
hyperphosphorylation of Ser2 in the RNAP2 CTD at
thousands of human genes. The loss of FUS leads to
RNAP2 accumulation at the transcription start site and
a shift in mRNA isoform expression toward early poly-
adenylation sites. Thus, in addition to its role in alter-
native RNA splicing, FUS has a general function
in orchestrating CTD phosphorylation during RNAP2
transcription.
Supplemental material is available for this article.
Received August 29, 2012; revised version accepted
November 12, 2012.
The RNA-binding protein FUS (fused in sarcoma) is im-
plicated in the pathology of several dissimilar diseases.
An oncogenic fusion protein resulting from a chromo-
somal translocation of the FUS gene occurs with a high
frequency in certain sarcomas (Hoell et al. 2011). Point
mutations in FUS cause or are associated with 5% of
familial amyotrophic lateral sclerosis (ALS) and 1% of
sporadic ALS cases (Mackenzie et al. 2010). FUS is a
nuclear protein, and the ALS mutations lead to varying
degrees of mislocalization to the cytoplasm (Kwiatkowski
et al. 2009; Vance et al. 2009). In patients, FUS is found
in aggregates in motor neurons for ALS or in neurons
of the frontal cortex in a related disease, frontal temporal
lobular dementia (FTLD) (Mackenzie et al. 2010). Famil-
ial ALS is typically a dominantly inherited disease, but
recessive inheritance has been reported (Kwiatkowski
et al. 2009). The extent to which the involvement of FUS
in ALS pathology is due to a gain of function (cytoplasmic
aggregation) or loss of its nuclear function is unknown.
To make this determination, the normal cellular function
of FUS needs to be better defined.
FUS has been proposed to regulate transcription by
RNA polymerase II (RNAP2) and RNAP3 (Wang et al.
2008; Tan et al. 2012), mRNA splicing, and mRNA
trafficking (Hoell et al. 2011; Ishigaki et al. 2012). FUS
coimmunoprecipitates with many proteins important to
transcription, including RNAP2 and the histone acetyl-
transferases CBP and p300 (Das et al. 2007; Wang et al.
2008). Transcription is linked to RNA processing (Munoz
et al. 2009; Kim et al. 2010), providing a possible common
denominator connecting reported FUS effects at various
levels of RNA metabolism. For this reason, we performed
a focused investigation of the role of FUS in transcription.
Results and Discussion
We tested the genome-wide localization of FUS on the
chromatin of HEK293T/17 cells using chromatin immu-
noprecipitation (ChIP) followed by next-generation se-
quencing (ChIP-seq) (Supplemental Table 1). Cells were
treated with a siRNA to knock down FUS expression
(siFUS), treated with a control siRNA of scrambled se-
quence (NEG), or left untreated (Fig. 1A). Where possible,
data sets from untreated cells were compared with those
from NEG-treated cells to ensure that no significant arti-
facts were caused by transfection.
Across expressed genes, we observed FUS enrichment
at transcription start sites (TSSs) (see Fig. 1B). Using the
peak-calling software FINDPEAKS, FUS was found to be
significantly associated with the annotated TSS of 9731
genes (68% of expressed genes, false discovery rate [FDR]
<0.05). This enrichment of FUS near the TSSs was lost
in siFUS-treated cells (Fig. 1B), demonstrating the effec-
tiveness of the knockdown and the specificity of the FUS
antibody used for ChIP-seq. We also performed ChIP-seq
on RNAP2 and detected a peak of RNAP2 at the TSS
overlapping that for FUS (Supplemental Fig. 1A; Supple-
mental Table 1). Our RNAP2 antibody, CTD4H8, binds
both unphosphorylated and Ser5-phosphorylated forms of
the YSPTSPS peptide, which is repeated 52 times within
the C-terminal domain (CTD) of RNAP2. The magnitude
of the FUS peak correlated with the magnitude of the
RNAP2 peak for expressed genes (R = 0.47, Pearson
correlation coefficient) (Supplemental Fig. 1B).
RNAi knockdown of FUS resulted in a modest but
significant increase in the accumulation of RNAP2 at the
TSSs of many genes (Supplemental Fig. 1C). The ‘‘travel-
ing ratio’’ measures the ratio of the density of RNAP2
near the TSSs (300 to +100 nucleotides [nt]) over that for
the rest of the gene body (Reppas et al. 2006; Rahl et al.
2010). An increase in the traveling ratio is consistent with
an increase in transcriptional pausing at or near the TSSs,
an increase in RNAP2 recruitment to the TSSs, or pre-
mature termination of transcription. In our negative
control treated cells and using the CTD4H8 antibody,
92% of expressed genes had a traveling ratio >2, which is
consistent with a previous genome-wide determination
of traveling ratios in mammals (Rahl et al. 2010). Upon
RNAi knockdown of FUS, FUS-bound genes underwent a
median twofold increase in their traveling ratios (Fig. 1C,
P! 1 3 1010, Student’s t-test). For many genes checked,
FUS knockdown led to increased RNAP2 levels near the
TSSs but did not result in changes in RNAP2 in the gene
body or changes in mRNA levels (Supplemental Fig. 1D,
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note inset bar graphs indicating change in mRNA levels).
Whether the RNAP2 accumulation is unproductive in
changing mRNA levels because of transcriptional paus-
ing or some other mechanism, such as premature termi-
nation, remains unknown at this point.
Further evidence of a direct role for FUS in regulating
transcription was observed in control treated cells. Genes
with the highest ratio of FUS to RNAP2 at the TSSs
had the lowest median traveling ratios, while genes with
the lowest levels of FUS had the highest traveling ratios
(Fig. 1D). There was a weak negative correlation between
the FUS/RNAP2 ratio and the traveling ratio (R = 0.24,
Pearson correlation coefficient) (Supplemental Fig. 2A),
consistent with FUS-bound genes having significantly
less transcriptional pausing. On the other hand, genes
with the lowest levels of FUS on average had less RNAP2,
lower mRNA levels, and flatter RNAP2 distributions
with lower traveling ratios. The traveling ratios of these
genes without FUS bound were unchanged by the siRNA
knockdown of FUS, consistent with this effect being due
to the presence of FUS and not an off-target effect of
the siRNA (Supplemental Fig. 2B). We tested whether
changes in the distribution of RNAP2 were accompanied
by global changes in Ser2 or Ser5 phosphorylation of the
RNAP2 CTD. Western blots for Ser2P and Ser5P did not
reveal changes in total phosphorylation of the RNAP2
CTD upon FUS knockdown (Supplemental Fig. 2C,D).
Canonically, RNAP2 CTD phosphorylation at posi-
tion Ser5 is prominent at the TSSs of genes, while Ser2
phosphorylation (Ser2P) accumulates downstream in the
gene body and toward the gene terminus (Ahn et al. 2004;
Kim et al. 2010). We performed ChIP-seq for Ser2P and
Ser5P using well-tested antibodies (H5 and ab5131, re-
spectively) for these marks on the CTD of RNAP2
(Supplemental Table 1; Rahl et al. 2010). In our negative
control cells, two-thirds of expressed genes (9741 genes)
displayed this canonical Ser2P distribution across the
gene. Upon knockdown of FUS, the Ser2P mark signifi-
cantly increased near the TSSs for those genes with FUS
bound (Fig. 2A; Supplemental Fig. 1C). Ser5P showed only
modest increases in accumulation near the TSSs (Supple-
mental Fig. 1C), consistent with the change in traveling
ratio described above. To test whether these effects could
be off-target effects of the siRNA, we performed knock-
down of FUS with a second siRNA and saw increases
in Ser2P at the TSSs for four genes checked by ChIP
followed by real-time PCR; the second siRNA gave less
FUS knockdown, and Ser2P increased to a lesser extent
(Supplemental Fig. 3A).
To analyze these striking changes in Ser2P further, we
ranked genes by the amount of FUS ChIP-seq reads
present at their promoters (Supplemental Fig. 3B). Genes
with the most FUS had the most prominent increase in
Ser2P upon FUS knockdown, and genes with the least
FUS present had a more muted response in Ser2P (Supple-
mental Fig. 4). We also noted that one-third of expressed
genes (4645 genes) had slightly to considerably higher
levels of Ser2P at the TSS than at the gene terminus. For
these noncanonical genes, those with the least FUS bound
to the TSSs had the highest average levels of Ser2P at
their TSSs (Fig. 2B; Supplemental Fig. 4). Because this
observation does not involve any siRNA knockdown, it
provides further support that Ser2P levels are regulated
by the presence of FUS.
The genome-wide FUS colocalization with RNAP2,
combined with its impact on RNAP2 CTD phosphoryla-
tion, could be explained by direct FUS–RNAP2 binding.
Indeed, FUS has been previously reported to immunopre-
Figure 1. FUS binds the TSSs of most expressed genes, and a loss
of FUS alters the distribution of RNAP2 on genes. (A) siFUS effec-
tively eliminated FUS protein expression in HEK293T/17 cells, as
seen by Western blot. (B) Using ChIP-seq, the density of FUS reads
was averaged across expressed genes (n = 14,317), revealing a local
accumulation of FUS near gene TSSs. This peak was lost when FUS
was knocked down by RNAi. The X-axis represents base pairs up-
stream of and downstream from the gene. Within the gene, the axis
is condensed into 10% windows (B1–B10) of the gene to correct for
different gene lengths. (C) The traveling ratio measures the ratio of
the density of RNAP2 near the TSS over that in the body of the gene.
Upon loss of FUS, this ratio increased for FUS-bound genes. (D) In
control NEG-treated cells, expressed genes were ranked by the ratio
of FUS to RNAP2, and the top 1000 genes (largest FUS/RNAP2 ratio)
were found to have lower traveling ratios than those of the bottom
1000 genes (the error bars represent the 25th and 75th percentiles).
Figure 2. Loss of FUS leads to an accumulation of Ser2-phosphor-
ylated RNAP2 near the TSSs. (A) Two-thirds of expressed genes have
canonical phosphorylation of RNAP2 CTD at Ser2P, which is low
near the TSS and increases toward the gene terminus. Upon loss of
FUS, inappropriate Ser2P is observed near the TSSs of FUS-bound
genes. The Y-axes represent the averaged number of reads. (B) One-
third of expressed genes have noncanonical Ser2P, with a higher
density of Ser2P near the TSSs. Of these 4645 genes, the 974 with
the lowest levels of FUS (Low FUS) have the highest levels of
noncanonical phosphorylation, on average.
FUS regulates Ser2 phosphorylation at RNAP2
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cipitate with RNAP2 from human cells (Das et al. 2007).
We performed immunoprecipitation of RNAP2 fromHeLa
cell nuclear extract using the antibody 8WG16, which was
raised against the hypophosphorylated CTD of RNAP2.
This sample was subjected to liquid chromatography
tandem mass spectrometry (LC-MS/MS), which identi-
fied FUS as a prominent binding partner (Supplemental
Fig. 5A). In fact, the most spectral counts identified by
LC-MS/MS, other than those from RNAP2 itself, matched
the FUS protein. Moreover, a protein highly homologous
to FUS, EWSR1, had the second most spectral counts
identified. FUS was visible by SDS-PAGE of the eluted
RNAP2 sample followed by silver staining, whereas a neg-
ative control (Fig. 3A, lane C) without antibody added did
not pull down FUS (Fig. 3A).
Because FUS regulated the phosphorylation of the CTD
of RNAP2, we further hypothesized that FUS bound to
the CTD. We therefore incubated recombinant purified
GST-tagged CTD with HeLa nuclear lysates to isolate
factors that bound the CTD. Our CTD construct con-
tained all 52 repeats of the human CTD of the RNAP2
subunit Rpb1. We again identified FUS by LC-MS/MS
within the eluted material (Supplemental Fig. 5A).
Since FUS bound GST-CTD in cell lysates, we tested
whether FUS could bind the CTD directly using purified
recombinant proteins. His6-tagged FUS (H6-FUS) was
incubated with GST-CTD bound to glutathione beads,
washed extensively with buffers containing nonionic de-
tergent and high salt, and eluted with glutathione. Eluted
FUSwas detected byWestern. FUS is also an RNA-binding
protein and binds the histone acetyltransferases p300 and
CBP in an RNA-dependent manner (Wang et al. 2008). For
this reason, FUS binding of the CTD was tested in the
presence and absence of nucleic acids using a sequence
found enriched in our FUS ChIP-seq data from the pro-
moter of the gene DNMT3B. FUS bound the CTD in an
RNA-dependent manner (Fig. 3B). dsDNA, ssDNA, and an
RNA–DNA hybrid of the same sequence and length did
not promote FUS binding to the CTD.
We tested whether FUS binding to the phosphorylated
forms of the CTD was RNA-dependent. This test was
important because although the CTD has an ability to
bind RNA, phosphorylation of the CTD has been shown
to destroy its ability to bind RNA (Kaneko and Manley
2005). To test whether FUS would bind phosphorylated
forms of the RNAP2 CTD, we incubated GST-CTD with
P-TEFb, TFIIH, or both kinases to phosphorylate Ser2,
Ser5, or both, respectively. The binding of FUS to the
phosphorylated CTD was still enhanced by the addition
of RNA to the reaction, which does not support a model
in which FUS is bound to the CTD simply through an
RNA bridge (Supplemental Fig. 5B). In addition, FUS
showed some ability to bind the Ser2P form of CTD
without RNA.
Although FUS bound the CTD in an RNA-dependent
manner in vitro, FUS may have other contacts with the
entire RNAP2 holoenzyme in an in vivo context. We
performed RNAP2 immunoprecipitations from HeLa
nuclear extracts after treatment with either RNase A to
eliminate RNA-dependent interactions or benzonase to
eliminate any nucleic acid-dependent interaction. FUS
immunoprecipitated with RNAP2 after treatment with
either benzonase or RNase A, which suggests that non-
RNA-dependent interactions exist in vivo between FUS
and the RNAP2 holoenzyme (Supplemental Fig. 5C,D).
We then explored whether FUS could directly inhibit
Ser2P of the CTD of RNAP2. Two kinases can phosphor-
ylate the CTD at position Ser2: P-TEFb (Marshall and
Price 1995; Ahn et al. 2004) and CDK12 (Bartkowiak et al.
2010; Blazek et al. 2011). P-TEFb is comprised of the
kinase CDK9 and a cyclin component—cyclin T1, T2, or
K (Rahl et al. 2010). We generated RNAi knockdowns
of CDK9 and CDK12 to test the requirement of these
kinases for the Ser2P increase observed upon FUS knock-
down (Supplemental Fig. 6A). Knockdown of CDK9 or
CDK12 eliminated the increase of Ser2P observed at the
TSSs due to siFUS treatment for the four genes tested
using Ser2P ChIP and real-time PCR (Fig. 4A). This
suggests that both CDK9 and CDK12 contribute to the
increased Ser2P observed with FUS knockdown. Consis-
tent with previous literature, knockdown of CDK9 or
CDK12 did not result in proportional reduction of total
Ser2P seen by Western (Supplemental Fig. 5E). Total
inhibition of Ser2P was achieved by treating cells with
1 mM nonspecific CDK inhibitor flavopiridol for 1 h
(Supplemental Fig. 3B). We also tested the hypothesis
that loss of FUS may alter the association of CDK9 with
RNAP2 using ChIP-seq. However, global CDK9 occu-
pancy was unaltered by FUS knockdown, suggesting
that FUS is not involved in P-TEFb recruitment or local-
ization (Supplemental Fig. 1C).
One possibility consistent with our data is that FUS
may directly prevent phosphorylation at position Ser2
of the CTD. We immunoprecipitated and purified active
CDK12 from a HeLa cell nuclear lysate using an antibody
developed by Arno Greenleaf (Duke University). Impor-
tantly, by Western, our purified CDK12 was free from
CDK9 contamination (Supplemental Fig. 5F). We incu-
bated recombinant P-TEFb or CDK12 with GST-CTD and
[g-32P]ATP. As expected, P-TEFb and CDK12 each effi-
ciently phosphorylated the CTD, as seen by gel electro-
phoresis and radiography. Upon addition of FUS, the
kinase activity of P-TEFb and CDK12 toward the CTD
was inhibited (Fig. 4B). Importantly, FUS did not affect
Figure 3. FUS associates with RNAP2 and binds the CTD of
RNAP2. (A) FUS immunoprecipitated with RNAP2 (lane IP) but
not with nonspecific IgG (lane C) from HeLa cell nuclear extract,
shown here by silver stain (left) and Western (right). (B) Recombinant
FUS (H6-FUS) bound the CTD of RNAP2 (GST-CTD) in an RNA-
dependent manner. H6-FUS was incubated with GST-CTD, bound to
glutathione beads, washed, eluted, and detected by Western. dsDNA,
ssDNA, and RNA–DNA hybrids, all of the same sequence and length,
were insufficient to promote FUS binding to the CTD.
Schwartz et al.
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P-TEFb phosphorylation of its own subunit, CDK9, sug-
gesting that FUS inhibits phosphorylation of the CTD
substrate rather than generally inhibiting P-TEFb kinase
activity. Also supporting this, we observed that a protein
copurified with FUS from Sf9 cells was also phosphory-
lated by P-TEFb. Again, FUS did not inhibit phosphory-
lation of this unknown substrate (Supplemental Fig. 6B).
The ability of FUS to block RNAP2 CTD phosphory-
lation by P-TEFb was not RNA-dependent. Even the
addition of RNase A to eliminate contaminating RNA
in the reaction did not reduce FUS inhibition of P-TEFb
(Supplemental Fig. 6B).
Our in vivo data would predict that FUS should inhibit
or delay the Ser2P specifically. To test this, we investi-
gated the effect of FUS on another kinase, TFIIH, which
phosphorylates the CTD at position Ser5 (Hirose and
Ohkuma 2007). Incubation of purified TFIIH with RNAP2
CTD and [g-32P]ATP resulted in efficient CTD phosphor-
ylation, as expected. The addition of FUS did not reduce
TFIIH-dependent phosphorylation of the CTD, consistent
with our in vivo observations (Fig. 4B).
Another possibility consistent with our data was that
FUS is a phosphatase that dephosphorylates Ser2 of the
CTD. To test this possibility, we prephosphorylated the
CTD with [g-32P]ATP using P-TEFb and stopped the re-
action by addition of either excess cold ATP or flavopiridol.
This phosphorylated CTD was then incubated with FUS
for 1 h at room temperature, much longer than our kinase
assays were allowed to proceed in Figure 4B. After incu-
bationwith FUS, no reduction in the 32P label was observed
from the CTD by radiography (Supplemental Fig. 6C),
providing evidence against phosphatase activity.
Finally, we investigated changes in mRNA levels and
RNA processing following FUS knockdown using RNA
sequencing (RNA-seq). We sequenced polyadenylated
RNA from three biological replicates of NEG-treated
control cells and three biological replicates of siFUS-
treated cells (Supplemental Table 1). From these experi-
ments, we aligned ;40 million paired-end reads per
sample at 90 nt long. We used a standard computational
approach to identify changes in gene expression and
splicing in our data sets. RNA-seq reads were mapped
to the University of California at Santa Cruz (UCSC) hg19
genome using Tophat 2.0.4, and reads were further ana-
lyzed for differential isoform expression using MISO.
MISO detected 101 genes with >0.2-fold change in
relative splicing isoform abundance and 33 genes with
changes in TSS usage (Fig. 5A; Supplemental Table 2).
Most of these changes were in minor isoforms of mRNAs
(Supplemental Fig. 7). The program Cufflinks 2.0 called
changes in splicing for only 50 genes, of which 11 were
also called by MISO (Supplemental Table 3). These num-
bers for HEK293T/17 cells are lower than those ob-
served in the human brain, where changes in splicing
were found for >300 genes (Lagier-Tourenne et al. 2012).
A simple explanation would be that these are tissue-
specific differences. Lowering the threshold for detec-
tion of changes in relative isoform abundance from 0.2
to 0.1 leads MISO to detect 271 changes in splicing, of
which 23 were detected by Cufflinks 2.0 (Supplemental
Fig. 8A; Supplemental Table 2).
Figure 4. FUS blocks phosphorylation of the CTD by known Ser2
kinases. (A) Using ChIP followed by real-time PCR, an increase in
Ser2P, on average, upon siRNA knockdown of FUS was detected at
the TSSs of these four genes checked. siRNA knockdown of CDK9
or CDK12 prevented the enhanced Ser2P signal resulting from the
loss of FUS (n = 2). (B) In vitro, FUS prevented recombinant purified
P-TEFb (middle) or purified CDK12 (right) from phosphorylating
CTD. (Left) FUS did not inhibit another CTD kinase, TFIIH. FUS
further did not prevent P-TEFb from phosphorylating the CDK9
subunit. Quantitation of CTD (Quant. CTD) represents quantitation
of the gel shown. The gels shown are representative of more than
three replicates.
Figure 5. Loss of FUS leads to changes in alternative splicing and
mRNA levels. (A) Changes in splicing and alternative start sites
(dark gray) were called by MISO using RNA-seq data from three
biological replicates of NEG- or siFUS-treated cells. Alternate last
exons were prevalent, often resulting in alternate 39 untranslated
regions (UTRs). Also observed were alternate exon inclusion or ex-
clusion, inclusion of introns, or alternative 59 or 39 splice site choice
(Alt 59 SS or Alt 39 SS, respectively). (B) A volcano plot shows only
the significantly changed genes called by Cufflinks 2.0 (n = 2163),
and changes greater than twofold are colored red. (C) Gene ontology
analysis using FuncAssociate 2.0 shows a significant number of
mitochondrial-associated genes regulated by a loss of FUS.
FUS regulates Ser2 phosphorylation at RNAP2
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Several of the observed FUS-dependent mRNA changes
were in choice of the last exon, which correlates with
alternative polyadenylation site choice. Twenty-five genes
showed shifts in the last exon with the higher threshold
for detection (Fig. 5A), and 89 genes showed shifts in the
last exon with the lower threshold for detection (Supple-
mental Fig. 8A). FUS knockdown led to production of
the shorter isoforms for 47 manually checked mRNAs
and longer isoforms for 15 mRNAs, consistent with the
previous finding that P-TEFb regulates 39 end processing
for mRNA (Supplemental Fig. 7; Ahn et al. 2004). Taken
together with our observed increase in traveling ratios,
this could argue that the loss of FUS leads to premature
polyadenylation or termination of transcription.
To identify RNAs bound by FUS, we performed CLIP-
seq of FUS in HEK293T/17 cells. In agreement with pre-
vious reports (Hoell et al. 2011; Ishigaki et al. 2012), we
found FUS bound to thousands of RNAs, meaning only
a minor fraction of those RNAs to which FUS is bound
have altered splicing in the presence of FUS (Supplemen-
tal Fig. 8C). FUS bound promiscuously to most mRNAs
and noncoding RNAs in the cell, and the density of CLIP-
seq reads somewhat correlated with the expression level
of the RNA transcript (R = 0.18, Pearson correlation
coefficient) (Supplemental Fig. 8B). FUS predominantly
associated with pre-mRNA toward the gene 59 ends in
agreement with a recent report (Supplemental Fig. 8C;
Ishigaki et al. 2012).
We evaluated changes in mRNA levels upon loss of
FUS. The software Cufflinks 2.0 called >2000 genes that
underwent a significant change in expression of >20%
(P < 0.01, Student’s t-test) (Fig. 5B; Supplemental Table 4).
In HEK293T/17 cells, twice as many genes showed in-
creased mRNA levels rather than decreased upon FUS
knockdown. However, the changes in gene expression
were small, mostly less than fourfold. Interestingly, the
most significant association was for genes that regulate
mitochondrial function (Fig. 5C).
Our finding that FUS binds near the TSSs is consistent
with previous reports of FUS binding gene promoters
(Tan et al. 2012). FUS knockdown resulted in a modest
increase in RNAP2 at TSSs (Supplemental Fig. 4) but
a reduced fraction of the RNAP2 within the gene body
(Fig. 1C; Supplemental Fig. 1D), with the net result that
total mRNA production was not substantially affected for
most genes. Although increased transcriptional pausing
is one possible explanation for the increase in the traveling
ratio upon the loss of FUS, the shift observed in mRNA
abundance toward isoforms with earlier polyadenylation
sites may indicate that premature termination contributes
to the increase. Unexpected in our findings was that FUS
binds and appears to affect transcription of thousands
of genes, consistent with FUS serving a function more like
that of a general transcription factor. The number of genes
to which FUS bound was considerably higher than ex-
pected based on previous reports (Das et al. 2007; Wang
et al. 2008; Tan et al. 2012).
Taken together, our data suggest that FUS modulates
the amount of Ser2P present near the TSSs because a loss
of FUS leads to an inappropriate overaccumulation of
Ser2P at the TSSs. We found that FUS can bind the CTD
of RNAP2 directly and that RNA can enhance FUS
binding in vitro. Because FUS immunoprecipitates with
RNAP2 from nuclear extracts after nuclease treatment,
the in vivo role of RNA in regulating the FUS–RNAP2
interaction requires further study. The following possi-
bilities are open for consideration: (1) RNA may recruit
FUS to bind the RNAP2 CTD in vivo but is not required
to maintain the interaction. (2) Even if RNA is required
to maintain the FUS–CTD interaction, the FUS–RNAP2
protein assembly may protect the key RNA fragment
fromRNase digestion. (3) Other factors may promote FUS
binding to the CTD in vivo.
Several groups have documented changes in splicing
upon loss of FUS, correlating the position of FUS bind-
ing on the pre-mRNA with changes in splicing (Hoell
et al. 2011; Ishigaki et al. 2012; Lagier-Tourenne et al.
2012). These reports and our studies agree that FUS binds
many more mRNAs than the relatively few that undergo
changes in splicing upon a loss of FUS. Our findings
further show that FUS binds and regulates RNAP2 Ser2P
at many more gene promoters than the number of genes
with documented defects in splicing. These effects on
splicing may be a separate function for FUS in addition to
its effects on transcription (for example, see Yamazaki
et al. 2012). On the other hand, these two processes may
be linked. Previous reports have documented links be-
tween the rate of RNAP2 elongation, its phosphorylation
state, and the choice of alternative splice sites (Munoz
et al. 2009). The knowledge that FUS affects both tran-
scription and RNAP2 CTD phosphorylation provides
incentive for future studies to determine what, if any,
relationship exists between these activities. In any case,
we suggest that regulation of splicing is not the only role
for FUS in cells and perhaps is not its major function.
In conclusion, our findings lead to a newmodel for FUS
activity in normal human cells. In this model, FUS binds
to the CTD of RNAP2 and inhibits premature Ser2
hyperphosphorylation of the CTD. The extent to which
the transcriptional effects and Ser2P modulatory func-
tions of FUS are connected or independent remains to be
determined. For example, P-TEFb is important for the
phosphorylation of elongation regulatory factors DSIF
and NELF (Yamaguchi et al. 1999). Whether FUS affects
phosphorylation of these factors is unknown, but it
could provide a simple mechanism for FUS regulation of
RNAP2 activity during the transition from initiation to
elongation.
This new model provides testable predictions to de-
termine whether a loss of FUS function occurs in motor
neurons of ALS disease patients. Interestingly, the onto-
logical association between genes affected by a loss of
FUS and regulation of mitochondrial function may be
relevant, since ALS is associated with changes in mito-
chondrial structure and activity (Cozzolino and Carri
2012). If a loss of function were caused by FUS mutations
in ALS, one would expect to find Ser2 hyperphosphoryla-
tion near the TSSs of a large number of genes in affected
tissues. Our finding that FUS prevents Ser2 hyperphos-
phorylation could provide a useful diagnostic and a basis
for subtyping ALS patients and may contribute to estab-




The siRNAs (Integrated DNA Technologies, Inc.) used were NEG
59-rCrCrUrCrArCrArUrGrGrArArCrGrArCrGrGrATT-39 annealed to its
complement, and siFUS 59-rCrGrGrArCrArUrGrGrCrCrUrCrArArArCr
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GrATT-39 annealed to its complement. Antibodies, ChIP protocols, and
additional siRNA sequences are in the Supplemental Material.
Pull-down assays and kinase assays
Recombinant FUS was expressed and purified as previously described
(Hoell et al. 2011). GST-CTD was recombinantly expressed in DE5 BL21
cells and purified. The RNA and DNA sequence added to pull-down
assays was ATTGAGGAGCAGCAGAGAAGTTGGAGTGAAGGCAGA
GAGGGGTTAAGG, which is found in the promoter of the geneDNMT3B.
More detailed protocols are in the Supplemental Material.
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Erratum
Genes & Development 26: 2690–2695 (2012)
FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2
Jacob C. Schwartz, Christopher C. Ebmeier, Elaine R. Podell, Joseph Heimiller, Dylan J. Taatjes, and Thomas R. Cech
In the above-mentioned article, the authors discovered that their sorting of genes showing noncanonical Ser2
phosphorylation was inverted. Genes denoted as ‘‘Very High FUS’’ in Supplemental Figure 4 should have been
‘‘Low FUS,’’ and genes denoted as ‘‘Low FUS’’ should have been ‘‘Very High FUS.’’ After this correction, both the
canonical and noncanonical Ser2 phosphorylated genes show an increase in Ser2 phosphorylated RNAP2 around the
transcription start site upon FUS knockdown, in support of our model. Figure 2B (below) and Supplemental Figure 4
(see Revised Supplemental Fig. 4 online) have been updated to reflect these corrected data. Also, on page 2691,
right-hand column, this single sentence ‘‘These noncanonical genes also responded to the loss of FUS by undergoing
a large increase in the levels of Ser2P near the TSS (Fig. 2B; Supplemental Fig. 4)’’ should replace these two sentences:
‘‘For these noncanonical genes, those with the least FUS bound to the TSSs had the highest average levels of Ser2P
at their TSSs (Fig. 2B; Supplemental Fig. 4). Because this observation does not involve any siRNA knockdown, it
provides further support that Ser2P levels are regulated by the presence of FUS.’’ All other next-generation sequencing
data sets have been independently reanalyzed and validated.
This correction does not change the main conclusions of the article, which is that FUS binds the CTD of RNA
polymerase II and regulates its phosphorylation at Ser2.
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